date:Feb 04, 2013
tive role in eye health. OPTISHARP is being used at 2mg dose/day, in combination with DSMs FloraGl Lutein, in the on-going study AREDS 2 (Age Related Eye Disease Study) sponsored by the National Eye Institute of the National Institutes of Health in the United States.
OPTISHARP is widely applied to nutritional supplements in several other regions of the world, and DSM says that this decision by the European Commission now offers companies in Europe the opportunity to add value to their products